Multiple myeloma vaccine - rEVO Biologics

Drug Profile

Multiple myeloma vaccine - rEVO Biologics

Latest Information Update: 21 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GTC Biotherapeutics
  • Developer GTC Biotherapeutics; Nonindustrial source
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics
  • 12 Mar 2001 Discontinued-I for Multiple myeloma in USA (Unknown route)
  • 13 Aug 1997 Phase-I clinical trials for Multiple myeloma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top